Subscribe
handshake-1
miodrag ignjatovic / iStockphoto.com
3 January 2018Americas

AstraZeneca sells US rights to four drugs for $46.5m

AstraZeneca has sold the US rights and New Drug Applications to four drugs to ANI Pharmaceuticals, a speciality pharmaceutical company.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia-Pacific
AstraZeneca sells Seroquel rights for $538m
10 May 2018   AstraZeneca has agreed to sell its rights to Seroquel (quetiapine fumarate) and Seroquel XR to China-based pharmaceutical company Luye Pharma Group for $538 million.
Big Pharma
UK government announces life sciences deal; GSK and AstraZeneca invest
11 December 2017   The UK government has announced a deal between the life sciences sector and the government, aimed at ensuring that the “next wave of breakthrough treatments” and innovative medical research and technologies are created in the country.
Asia
AstraZeneca forms Chinese company to boost innovation
28 November 2017   AstraZeneca and the Chinese Future Industry Investment Fund have partnered to establish a company focused on discovering, developing and commercialising new medicines.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Asia-Pacific
AstraZeneca sells Seroquel rights for $538m
10 May 2018   AstraZeneca has agreed to sell its rights to Seroquel (quetiapine fumarate) and Seroquel XR to China-based pharmaceutical company Luye Pharma Group for $538 million.
Big Pharma
UK government announces life sciences deal; GSK and AstraZeneca invest
11 December 2017   The UK government has announced a deal between the life sciences sector and the government, aimed at ensuring that the “next wave of breakthrough treatments” and innovative medical research and technologies are created in the country.
Asia
AstraZeneca forms Chinese company to boost innovation
28 November 2017   AstraZeneca and the Chinese Future Industry Investment Fund have partnered to establish a company focused on discovering, developing and commercialising new medicines.

More on this story

Asia-Pacific
AstraZeneca sells Seroquel rights for $538m
10 May 2018   AstraZeneca has agreed to sell its rights to Seroquel (quetiapine fumarate) and Seroquel XR to China-based pharmaceutical company Luye Pharma Group for $538 million.
Big Pharma
UK government announces life sciences deal; GSK and AstraZeneca invest
11 December 2017   The UK government has announced a deal between the life sciences sector and the government, aimed at ensuring that the “next wave of breakthrough treatments” and innovative medical research and technologies are created in the country.
Asia
AstraZeneca forms Chinese company to boost innovation
28 November 2017   AstraZeneca and the Chinese Future Industry Investment Fund have partnered to establish a company focused on discovering, developing and commercialising new medicines.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB